(Q36594711)

15 August 2017

1 reference

title

Targeted approaches for treating advanced clear cell renal carcinoma (English)

1 reference

15 August 2017

author name string

Dick Johan van Spronsen

series ordinal

1

1 reference

15 August 2017

Pieter H M De Mulder

series ordinal

2

1 reference

15 August 2017

publication date

6 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

29

1 reference

15 August 2017

issue

8-9

1 reference

15 August 2017

page(s)

394-402

1 reference

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

15 August 2017

cites work

1 reference

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

Systemic therapy for renal cell carcinoma

21 January 2018

1 reference

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

21 January 2018

1 reference

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

Mechanisms and future directions for angiogenesis-based cancer therapies

21 January 2018

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

BAY 43-9006: preclinical data

21 January 2018

1 reference

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

21 January 2018

1 reference

Mammalian target of rapamycin inhibition

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Novel endpoints and design of early clinical trials

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000094250

1 reference

15 August 2017

1 reference